Sartorius Stedim Biotech Shareholders’ Equity Growth & History (DIM)
Sartorius Stedim Biotech's shareholders’ equity was €4.09B for fiscal 2025.
View full Sartorius Stedim Biotech company overviewSartorius Stedim Biotech annual shareholders’ equity history
| Fiscal year | Period ended | Shareholders’ equity | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €4.09B | €103.9M | +2.61% |
| 2024 | 2024-12-31 | €3.99B | €1.35B | +51.09% |
| 2023 | 2023-12-31 | €2.64B | €189.2M | +7.72% |
| 2022 | 2022-12-31 | €2.45B | €793.4M | +47.91% |
| 2021 | 2021-12-31 | €1.66B | €217.8M | +15.14% |
| 2020 | 2020-12-31 | €1.44B | — | — |
Sartorius Stedim Biotech quarterly shareholders’ equity
| Fiscal quarter | Period ended | Shareholders’ equity | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | €4.24B | €233.3M | +5.83% |
| Q1 2026 | 2026-03-31 | €4.11B | €136.1M | +3.43% |
| Q4 2025 | 2025-12-31 | €4.09B | — | — |
| Q2 2025 | 2025-06-30 | €4.00B | — | — |
| Q1 2025 | 2025-03-31 | €3.97B | — | — |
Sartorius Stedim Biotech shareholders’ equity trends
Over the last five fiscal years, Sartorius Stedim Biotech's shareholders’ equity increased from €1.44B to €4.09B, a change of €2.65B. The latest reported quarter, Q2 2026, shows €4.24B.
What shareholders’ equity means
Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.
reported shareholders’ equity
TickerStat standardizes stockholders’ or shareholders’ equity reported in company official filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sartorius Stedim Biotech source filings ↗